+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Noncontact Holmium: YAG Laser Thermal Keratoplasty to Correct Hyperopia: 18-Month Follow-Up

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Purpose: To assess the safety and efficacy of noncontact holmium:yttrium aluminium garnet laser thermal keratoplasty (Ho: YAG LTK) for correction of low to moderate hyperopia. Methods: We performed noncontact Ho:YAG LTK on 1 eye each of 28 patients for correction of hyperopia up to +3.88 dpt. Treatments were conducted with 1 or 2 symmetrical octagonal rings of 8 spots/ring with centerline diameters of 6 mm (1 ring) or 6 and 7 mm (2 rings), 10 pulses of laser light at 5 Hz pulse repetition frequency, variable pulse energy in the range of 208-242 mJ and a nominal spot diameter between 615 and 623 µm. Results: At 18 months after surgery, 20 of 22 (91%) treated patient eyes had improved uncorrected distance visual acuity The mean change in subjective manifest refraction (spherical equivalent) was ––0.52 ± 0.35 dpt and ––1.41 ± 0.53 dpt for 1- and 2-ring treatment groups, respectively, with good stability in the refractive change after 6 months. The mean induced refractive astigmatism was small (0.30 ± 0.37 dpt/0.25 ± 0.29 dpt for 1-/2-ring treatments). None of the eyes lost 2 or more lines of spectacle-corrected distance visual acuity. There were no clinically significant changes in glare and contrast sensitivity. Conclusions: Noncontact LTK treatment of low hyperopia is safe and effective, and it is more stable and less prone to induce astigmatism than previously reported contact mode LTK treatments.

          Related collections

          Author and article information

          S. Karger AG
          01 April 2010
          : 211
          : 5
          : 274-282
          aCullen Eye Institute, Baylor College of Medicine, Department of Ophthalmology, Houston, Tex., and bDoheny Eye Institute, University of Southern California, Department of Ophthalmology, Los Angeles, and cSunrise Technologies, Inc., Fremont, Calif, USA; dDepartment of Ophthalmology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
          310808 Ophthalmologica 1997;211:274–282
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Original Paper


          Comment on this article